Ocean Biomedical Announces U.S. Patent Issued for Bispecific Cancer Immunotherapy Treatment With Demonstrated Killing of Tumor Cells

  • Investing.com
Ocean Biomedical Announces U.S. Patent Issued for Bispecific Cancer Immunotherapy Treatment With Demonstrated Killing of Tumor Cells

Ocean Biomedical, Inc. (OCEA) announced today that a new, broad U.S. patent for bispecific antibodies targeting chitinase 3-like-1 (CHi3L1) and programmed cell death protein 1 (PD-1), a promising new approach that has emerged from prior breakthrough discoveries that CHi3L1 is a “master regulator” of tumor growth in multiple visceral cancers, has been issued to one of its Scientific Co-founders, Dr. Jack A. Elias, MD.

Ocean Biomedical’s bispecific antibody is a cutting-edge immunotherapy approach that demonstrates promising synergy by combining Ocean’s proprietary anti-CHi3L1 antibody with existing immune checkpoint inhibitors that target PD-1 in a bispecific-antibody format. As seen in the image below, these bispecific antibodies have been shown to synergistically kill tumor cells at levels dramatically exceeding the effectiveness of either the anti-CHi3L1 antibody or the anti-PD-1 antibody alone—in multiple cancer types and multiple animal models.

Ocean Biomedical’s breakthrough comes at a critical time for the evolving immuno-oncology sector, which is working to realize the promise of immune checkpoint inhibition. Current challenges include the limited number of cancer patients demonstrating initial responses and the significant number of responders relapsing following classic immune checkpoint blockade. Ocean Biomedical’s new approach combines Ocean’s anti-CHi3L1 antibody with classic immune checkpoint blockade, and the initial magnitude and duration of response from Ocean’s bispecific immunotherapy treatment in multiple animal models of visceral cancer was synergistically enhanced compared to immune checkpoint blockade alone.

The new bispecific patent has been granted for prostate cancer, colon cancer, rectal cancer, ovarian cancer, kidney cancer, breast cancer, glioblastoma, melanoma, and lung cancer. The newest claims dovetail with and fortify recently issued patents with claims coverage focused on composition of matter of monoclonal antibodies targeting and inhibiting CHi3L1.

“This bispecific antibody pathway discovery is a monumental leap forward. By controlling CHi3L1 and concurrently targeting PD-1, you don’t just control one anti-cancer pathway, you simultaneously control many anti-cancer pathways,” said Dr. Elias. “We believe our discoveries will advance cancer research, and eventually treatment and patient outcomes, forward.”

“Seeing Dr. Elias’ revolutionary work receive this important patent is exciting. The Ocean Biomedical team is working to take the systematic steps needed to progress the anti-CHi3L1 bispecific antibodies into the clinic to potentially become powerful new cancer therapeutics,” commented Ocean Biomedical’s CEO, Elizabeth Ng.

“These discoveries have the potential to save thousands of lives of people affected not just by lung metastasis and melanoma but also by glioblastoma and other forms of cancer,” commented Dr. Chirinjeev Kathuria, Ocean Biomedical’s co-founder and Executive Chairman.

Dr. Jack A. Elias is the former Chair of Yale’s Department of Internal Medicine, Dean Emeritus of Medicine and Biological Sciences at Brown University, and current Professor of Translational Science, Medicine and Molecular Microbiology and Immunology at The Warren Alpert Medical School of Brown University. He is a leading pulmonary care specialist and research pioneer. In 2019, Dr. Elias co-founded Ocean Biomedical with several Brown University colleagues, alums, and experienced pharma business leaders to help address major unmet medical needs by accelerating more discovery science into needed therapeutics.

Drop an image here or Supported formats: *.jpg, *.png, *.gif up to 5mb

Error: File type not supported

Drop an image here or


Related Articles